If you’ve dipped even a toe into the muddy waters of 510(k) submissions, you already know one big truth: pick a predicate wisely, as it can make or break your entire submission. And if FDA doesn’t agree with your logic? Then expect to see that big red “substantial equivalence denied” stamp all over your submission documentation.
Predicate selection is the strategic backbone of your regulatory approach—and it determines how smooth (or chaotic) the rest of your submission process will be. And it’s not a surface-level similarity game. It’s a deep structural comparison of intent, technology, risk, and performance.
Let’s break down how to choose correctly so you avoid common pitfalls and keep FDA from raising those dreaded “new questions of safety and effectiveness.”
Start With Your Predicate Comparison Table: The Regulatory Report Card
Every 510(k) requires a predicate comparison table—basically the FDA equivalent of setting your device next to the predicate and showing, point by point, why they are substantially equivalent. You’ll be comparing things like intended use, indications for use, technological characteristics, materials, patient-contact details, dimensions, and performance. But the key isn’t the comparison itself—it’s how you justify the differences.
In the table, you’ll categorize each feature as the same, similar, or different. The trick? If you say “different,” FDA wants proof that the difference doesn’t introduce new safety or effectiveness concerns. And honestly, even when you say “similar,” you should be ready to defend it because FDA will not take your word for it.
This comparison table sets the stage for the entire submission, so treat it like a graded assignment where “show your work” is mandatory.
Intended Use and Indications for Use Come First
FDA always starts at the top: What does your device do? Who is it for? Under what conditions is it used?
Changing your indications for use—even if the underlying technology is the same—can shift your regulatory path entirely. If a red-light device originally cleared for cold sores is suddenly being proposed for wrinkles, that’s not just access to a whole new market segment – it’s a whole new 510(k). Different anatomical regions, different exposure concerns, and different clinical endpoints equal a whole new conversation with the agency.
Patient population changes, particularly moves into pediatrics, also trigger deeper scrutiny. Pediatric patients are a protected class, and FDA typically expects clinical evidence to support their inclusion.
Duration matters, too. Turning a seven-day device into a thirty-day device isn’t a small tweak—FDA will absolutely question whether the longer duration increases risk, and whether any risk is worth the benefit.
Technological Characteristics Matter More Than You Think
Even seemingly small technological differences can raise red flags, and FDA expects you to understand and explain how each difference affects safety and performance.
For example, light-based therapies must address wavelengths, energy levels, and exposure risks. Software-based devices must tackle user-interface changes and cybersecurity requirements. And implantable devices require a deep look at materials, long-term stability, and compatibility with anatomy.
What seems “close enough” to you may be a huge deal to FDA. Their favorite question is : Does this difference introduce any new questions of safety or effectiveness? (I did warn you). And you must be ready to answer that clearly.
How Old Is Too Old? It Depends on Your Technology
FDA used to suggest an informal window for picking predicates released within the last five to ten years—but today, the acceptable predicate age depends entirely on your device type.
For software, digital health, or AI/ML, FDA basically wants predicates that still have a new-car smell. Anything more than a few years old risks being considered outdated, especially if it predates modern cybersecurity or usability expectations. And no—arguing that your predicate “didn’t have to do those tests” will not get you out of doing them now (and I’ve had clients who tried).
For implants, the rule flips. FDA prefers predicates with a long, stable commercial history, because longevity indicates a strong safety and effectiveness profile. If you’re modifying an implant for pediatrics, longevity becomes even more critical—and clinical evidence usually enters the chat, so think long and hard before committing to a pediatric application.
Don’t Skip Post-Market Surveillance Research
One of the most overlooked parts of predicate selection is evaluating the predicate’s real-world performance. If you pick a predicate with a history of recalls, adverse events, or user complaints, FDA will question why you thought it was an appropriate comparator (as they should).
In other words: Don’t pick a predicate with a rap sheet. It doesn’t help your case.
What About FDA’s New Predicate Guidance?
A few years ago, FDA issued draft guidance that essentially asked companies to publicly justify:
-
which predicates they evaluated,
-
why they ruled others out,
-
and what post-market data they reviewed.
This caused what the transcript generously calls a kerfuffle, because – surprise, surprise – medical device companies don’t want competitors reading their entire regulatory playbook.
These guidances are still drafts, and they’re unlikely to become requirements in their current form. But they absolutely reveal where FDA’s thinking is headed—toward transparency, technology-appropriate predicate age, and safety-driven justification.
Ignoring that direction would be… unwise.
Use the Pre-Sub. Seriously.
If there’s one thing you take away from this post, let it be this: Use a pre-submission meeting to confirm your predicate strategy before you start drafting a 510(k). It is the single best way to test your logic, uncover hidden issues, and avoid FDA surprises months into your submission.
A pre-sub lets FDA react to your intended use, indications, technological comparisons, and testing plans early—before you’re locked in.
Skipping this step means choosing the “expert mode” version of the 510(k) process for no reason at all.
Final Thoughts: Your Predicate Strategy Sets the Entire Tone of Your 510(k)
If your predicate logic doesn’t pass your internal sniff test, it definitely won’t pass FDA’s. Predicate selection isn’t a choice to be made lightly—it’s the foundation of your substantial equivalence argument and your entire regulatory pathway.
The more strategic you are early on, the cleaner, faster, and more successful your submission will be.
And if you want help navigating predicate options, evaluating product codes, or building a defensible 510(k) pathway, I’m always here to help.
Watch the full podcast discussion on YouTube: https://youtu.be/eXIEda9Hzec
Or listen on Spotify: https://open.spotify.com/episode/3rgq9eOOHOYwYTgjYEM9lG?si=72bdab5e59004286
And read more about predicate devices here: https://leanraqa.com/choosing-the-right-predicate-device/
